VEGFA and Abnormal retinal morphology: Among anti-VEGF agents, bevacizumab is often used intravitreally to handle several retinal diseases (Falavarjani and Nguyen, 2013; Reibaldi et al., 2014; Dossarps et al., 2015; Platania et al., 2015; Plyukhova et al., 2020; Yousef et al., 2020; Toro et al., 2021).